Latest news with #ABCL
Yahoo
2 days ago
- Business
- Yahoo
AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 ('the '408 Patent'). The patent specifically covers microfluidic devices and their application in culturing and selectively recovering cells. Previously, Bruker Cellular Analysis Inc., which is a subsidiary of Bruker Corporation (NASDAQ:BRKR), had challenged the claims of the '408 Patent. Bruker argued for the patent's invalidity based on allegations of anticipation and obviousness in light of prior art. However, the US Patent Trial and Appeal Board/PTAB rejected all of Bruker's arguments. The CAFC's recent decision further confirms the validity of all claims within AbCellera's '408 Patent. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. The 408 Patent is an integral part of ongoing multi-patent infringement litigation between AbCellera and Bruker, which is currently pending in the US District Court for the Northern District of California. AbCellera intends to continue defending its intellectual property portfolio and looks forward to proving its infringement case against Bruker in the District Court. AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US. Bruker Corporation (NASDAQ:BRKR) develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
India.com
5 days ago
- Entertainment
- India.com
Made for Rs 13 crore, this Amitabh Bachchan movie was a huge flop, didn't even recover its budget, earned only Rs... movie is..., lead actress is...
Amitabh Bachchan is one of the biggest actors in the Bollywood industry. It has been over 5 decades that the actor has been in Indian cinema. While the majority of his films are hits, there are times when the actor gave flop movies. Today, we will discuss one such film of Amitabh Bachchan which did not even recover its budget. Not just that, even Amitabh's wife Jaya couldn't stand the film. This film was released in 1997 and featured Karisma Kapoor in the lead role. Amitabh wanted to make a comeback with the film. However, little did he know the movie he thought would be a hit would eventually become a flop. If you are wondering which film we are talking about, then the movie in discussion is Mrityudaata. About Mrityudaata The movie was made for Rs 14 crore and was directed by Mehul Kumar. However, the performance was so poor that it could not even recover the budget. The film was produced by Amitabh Bachchan's company ABCL. Opposite Amitabh was Dimple Kapadia. In one of the interviews, Amitabh Bachchan said that during the screening of the film, his wife Jaya told him that the movie would not work. And whatever the veteran actress said turned out to be true. In another interview, Amitabh accepted that his film Mrityudaata did not work and was a huge flop. He also said that for the failure, he held himself responsible. According to reports, Mrityudaata only earned Rs 8 crore—literally half of the budget.
India.com
6 days ago
- Entertainment
- India.com
This 28 year old film of Amitabh Bachchan was his biggest flop, even Jaya Bachchan walked out at the interval, film is.., lead actress was...
This 28 year old film of Amitabh Bachchan was his biggest flop, even Jaya Bachchan walked out at the interval, film is.., lead actress was... The megastar of Indian cinema, Amitabh Bachchan, has dominated Bollywood for decades with his famous roles and historic blockbusters. From the 'angry young man' of the 70s to his powerful characters in modern films, Bachchan has won the admiration and affection of generations. Although the majority of his films have been successful, not every film in his career was a hit. The film that we are talking about is none other than Mrityudaata. Released 28 years ago, this film stands to be the biggest career failure in Amitabh Bachchan's remarkable career. Produced by his own company ABCL and directed by Mehul Kumar, hopes were high. The supporting cast featured some strong performers like Karishma Kapoor, Paresh Rawal, Pran, and Dimple Kapadia opposite Amitabh, but no amount of anticipation could prepare audiences for the disaster Mrityudaata would become. What's surprising is that his wife, Jaya Bachchan, understood the fate of this movie early on. During the preview screening, she left at the interval. That was enough for Amitabh to know something was wrong. When he asked her why she left, Jaya replied that she had found the film boring, and it had not engaged her from the start. Much self-honesty as those predictions were, they were sadly true. The audience's lack of engagement and Dimple and Amitabh's on-screen chemistry did not create any lasting impression. The film failed to recover its budget as a commercial endeavor at the box office. Amitabh later took responsibility for the flop, admitting the film did not live up to expectations and he was partly to blame for finding it not good enough. After scoring a hit after a hit in the 70s and 80s, he was facing a series of flops, which started to erode his persona. Mrityudata, rather than being a comeback film, was just one more film on the wrong side of the ledger. Failure, however, is a reminder that legends also have lows and is, as always, an opportunity for courage, recognition of it, and rising again.
Yahoo
09-06-2025
- Business
- Yahoo
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio's Substack. In this article, we will summarize the bulls' thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2nd June. ABCL's trailing P/E was 19.92 according to Yahoo Finance. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. Abcellera is approaching a potential inflection point as it advances two new molecules—ABCL575 and ABCL635—into clinical trials, signaling its progress from a platform with promise to one capable of solving real-world medical problems. ABCL575 targets the OX-40 pathway, a critical immune regulator, and is being trialed for atopic dermatitis, with broader implications for treating alopecia and other chronic conditions that often stem from underlying viral or bacterial infections. CEO Carl Hansen noted that the same mechanism might have therapeutic value across autoimmune disorders, cancers, and infectious diseases, making OX-40 a cornerstone of Abcellera's ambitions. Meanwhile, ABCL635 targets the NK3R receptor in the brain's infundibular nucleus, effectively regulating endocrine balance and alleviating menopausal hot flashes. Since NK3R is part of the expansive GPCR receptor family, success here could validate Abcellera's ability to target a vast range of physiological functions, from hormone control to mood and sensory regulation. Both candidates exemplify the same core strength of Abcellera's platform: designing molecules with highly specific shapes to achieve precise biological effects. This shape-function relationship underpins the company's long-term vision of building a foundational biotech platform capable of producing tailored therapeutics. Although Abcellera's current financials remain weak, reflecting high risk, clinical success would dramatically increase its operating leverage and establish its relevance across a wide therapeutic spectrum. The platform's success could mirror and complement businesses like Hims, where data on bodily processes meets Abcellera's molecular solutions. While early in its journey, Abcellera's emerging capabilities suggest transformative potential if early trials succeed. Previously, we have covered ABCL in January 2025 wherein we summarized a by Jack Prescott on Twitter. The author highlighted the company's differentiated antibody discovery platform, which used microfluidics and AI to support an asset-light, partnership-driven model with firms like Eli Lilly and Moderna. Despite setbacks post-COVID, AbCellera maintained strong financials with $700M in cash, minimal debt, and over 200 pipeline programs, while its new GMP facility and government support positioned it for future clinical and commercial growth. Unfortunately, his thesis did not play out and the stock is down 26% since our coverage. However, due to the company's recent advances in the clinical trial process of two new molecules, we are optimistic about Antonio's thesis. AbCellera Biologics Inc. (ABCL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held ABCL at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
India.com
25-05-2025
- Entertainment
- India.com
Amitabh Bachchan once went bankrupt and it affected Mukul Dev's career in Bollywood due to...
Bollywood actor Amitabh Bachchan is the epitome of versatility. The actor has been contributing to Indian cinema for decades. Despite turning 82 years old, he has not stopped working. Amitabh Bachchan was last seen in the superhit film Kalki 2898 AD and the Shahenshah actor hosts the very famous quiz show Kaun Banega Crorepati. As a result, Amitabh Bachchan stands in the sixth spot in the top 10 richest Bollywood actors. However, while today Amitabh has all the luxury to himself, things were not the same when he started his own production house, ABCL. The actor faced many challenges and even bankruptcy. However, a chain reaction of events played a crucial role in launching the career of the late actor, Mukul Dev. Interesting right! Scroll down to read more. Do you know that Amitabh Bachchan's production house had signed Mukul Dev for his debut?! Yes, that's correct! In an interview, the late actor opened up on the matter and revealed that Jaya Bachchan had approached him with the offer to act in one of the three films which were being made by Big B's production company. He revealed that an advance payment of Rs 75,000 was also given to him. In the interview, Mukul Dev said, 'When she met me she had said, 'I want to sign you. We are making three films and you are doing at least one film with us among the three films that we are producing. I don't know which of these films you will do but you will do a film with us.'' The name of the film was Naam Kya Hai and it would have marked Mukul's debut in Bollywood. However, that never happened as the production house ran into financial loss and all the films that were being produced during that tenure were shelved. In a conversation with Planet Bollywood, the actor stated that Amitabh Bachchan had to face massive loss due to which the 2-3 movies which were made were never released. Amitabh Bachchan's company ABCL was facing major losses in the late 90s. In an interview with Vir Sanghvi, he opened up on the same and revealed that the company was of Rs 60 crore and it faced a loss of Rs 70 crore. Additionally, a debt of Rs 22 crore was on Big B's head. By the time Mukul Dev's movie was about to release, Amitabh Bachchan had incurred a loss of Rs 90 crores. As a result, Amitabh had no choice but to cancel the release. Meanwhile, Mukul Dev said goodbye to the world on May 24, 2025. The actor was not keeping well for a long time and passed away at the age of 54. He is survived by his brother Rahul Dev.
